Respiratory Conditions

Therapies targeting extracellular matrix remodeling might hold the most promise.

Targeting S100A4 with a monoclonal antibody could comprehensively dampen disease-causing pathways, say drug developers.

CEO Scott Staszak spoke to Managed Healthcare Executive about the creation of a patient registry and other accomplishments.

Investigational interstitial lung disease (ILD) drug, efzofitimod, shows early signs of efficacy in patients with pulmonary sarcoidosis and SSc-ILD (scleroderma-related ILD), according to new trial data.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

The letter, signed by 79 medical societies, expresses concern over recent federal immunization review policies and asks that vaccines remain available to patients without cost-sharing.

More cases of interstitial lung disease (ILD) in India can be traced back to occupational exposure and other environmental causes compared with ILD in the U.S. A different set of exposures may affect the symptoms and course of the disease.

The Arthritis Foundation is funding a study to help predict the onset and progression of interstitial lung disease in rheumatoid arthritis patients

Kaminski and his colleagues were pioneers in applying high-throughput, genome-scale transcript profiling to advanced lung disease.

CDC researchers report a rate of 7.1 per 100,000, an increase from 5.3 per 100,000 in a previous study. But improved diagnosis of idiopathic pulmonary fibrosis might be a factor.

An already approved cancer drug, Yervoy (ipilimumab), improved lung repair ability in a study of mice with idiopathic pulmonary fibrosis.

Researchers found that use of immunosuppressive medication was a strong protective factor, associated with a 60% reduction in mortality.

Research 'marries' traditional pathology with genomics.

The fundraiser is inspired, in part, by Michael Kuchwara, a famed Associated Press theater critic who died from pulmonary fibrosis in 2010

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research breakthroughs, the drug pipeline, and the Supplemental Oxygen Access Reform (SOAR) Act in an interview with Managed Healthcare Executive.

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B inhibitor as a treatment for progressive pulmonary fibrosis.

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved quality of life and functional capacity as measured in the 6-minute walk distance test.